Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEXSEN LIMITED Major Shareholding Notification 2026

Feb 26, 2026

65466_rns_2026-02-26_de7eb15f-7f6f-42b6-85c7-d7ac63e36153.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

ASX Release | 27 February 2026

==> picture [109 x 61] intentionally omitted <==

==> picture [378 x 18] intentionally omitted <==

Nexsen Limited (ASX:NXN) (“Nexsen” or the “Company”) provides the following Notice of Change of Interests of Substantial Holder in relation to itself. The disclosure requirement arises from the release of 14,200,000 Fully Paid Ordinary Shares from ASX-imposed mandatory escrow this week.

The securities released this week were held by pre-IPO investors in the Company.

==> picture [25 x 8] intentionally omitted <==

ASX release authorised by the Managing Director.

==> picture [187 x 11] intentionally omitted <==

Corporate Enquiries Company Secretary Nexsen Limited Reign Advisory e: [email protected] e: [email protected] w: nexsen.bio p: + 61 2 9174 5388

Suite 1005, 4 Bridge Street Sydney NSW 2000

Scan the QR code to join Nexsen’s Investor Centre or visit https://investors.nexsen.bio

==> picture [61 x 60] intentionally omitted <==

==> picture [141 x 12] intentionally omitted <==

==> picture [26 x 12] intentionally omitted <==

Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen’s lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

==> picture [596 x 54] intentionally omitted <==

----- Start of picture text -----

Nexsen Limited nexsen.bio
ASX:NXN ACN 655 182 497
----- End of picture text -----

604 page 1/2

15 July 2001

Form 604

Corporations Act 2001 Section 671B

Notice of change of interests of substantial holder

To Company Name/Scheme NEXSEN LIMITED (ASX:NXN) ACN/ARSN 655 182 497

1. Details of substantial holder(1)

Name NEXSEN LIMITED (ASX:NXN) and its controlled entities

ACN/ARSN (if applicable) 655 182 497

There was a change in the interests of the substantial holder on 25/02/2026 The previous notice was given to the company on 06/02/2026 The previous notice was dated 06/02/2026

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4) Previous notice Previous notice Present notice Present notice
Person’s votes Voting power (5) Person’s votes Voting power (5)
Fully Paid Ordinary Shares (FPO) 121,630,104
60.7%

107,430,104

53.7%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company are as follows:

Date of
change
Person whose
relevant
interest
changed
Nature of change (6) Consideration
given in relation
to change (7)
Class and
number of
securities
affected
Person’s
votes
affected
25/02/2026 Nexsen Limited Ceasing of restrictions on the
disposal of shares under mandatory
escrow arrangements imposed by
the Company in accordance with
the ASX Listing Rules

N/A
14,200,000 FPO 14,200,000

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant
interest

Registered
holder of
securities
Person
entitled to be
registered as
holder(8)
Nature of relevant interest (6) Class and
number of
securities
Person’s
votes
Nexsen Limited Refer to
Annexure B
Refer to
Annexure B
Restrictions on the disposal of shares under
mandatory escrow arrangements imposed by the
Company in accordance with the ASX Listing
Rules result in the Company having a technical
relevant interest in its own shares that requires
disclosure under section 671B of the
Corporations Act 2001(Cth) (theAct) by virtue of
section 671B(7)(c) of the Act. However, the
Company has no rights of acquisition or voting
over these shares and does not hold a relevant
interest in these shares by virtue of section
609(9B) of the Act (other than for disclosure
purposes under section 671B of the Act).

107,430,104 FPO
107,430,104

Further information is available in the Company’s Prospectus (released on ASX 10 October 2025) and Annexure A to this form provides a model of the restriction notices that have been issued.

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable) Nature of association None. N/A Addresses The addresses of persons named in this form are as follows: Name Address Nexsen Limited Suite 1005, 4 Bridge Street, Sydney NSW 2000

6. Addresses

The addresses of persons named in this form are as follows:

Signature

print name SONNY DIDUGU capacity COMPANY SECRETARY, NEXSEN LIMITED sign here date 27 FEBRUARY 2026

DIRECTIONS

  • (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.

  • (2) See the definition of "associate" in section 9 of the Corporations Act 2001.

  • (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

  • (4) The voting shares of a company constitute one class unless divided into separate classes.

  • (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

  • (6) Include details of:

  • (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

  • (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, becom`e entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

(8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Annexure A – Restriction Notices Model

==> picture [534 x 755] intentionally omitted <==

==> picture [534 x 754] intentionally omitted <==

Annexure B – Listing of All Escrowed Holders

SHAREHOLDER SHARES
SUBJECT
TO
ESCROW
ESCROW PERIOD
FREDRONN PTY LTD 150,000 24 months from quotation date
KAELIS FLINN BALL 125,000 24 months from quotation date
RONNYMAX PTY LTD 25,000 24 months from quotation date
RUTHIE PTY LTD 100,000 24 months from quotation date
VIDOG CAPITAL PTY LTD 1,000,000 24 months from quotation date
CAPITAL CORPORATION (HOLDINGS) 931,700 24 months from quotation date
KIMBERLEY DAWN HANLY + THOMAS SYLVANUS HANLY HANLY FAMILY SUPERFUND> 169,400 24 months from quotation date
AJAVA HOLDINGS PTY LTD 3,998,000 24 months from quotation date
AJAVA HOLDINGS PTY LTD 1,999,000 24 months from quotation date
APEX CONSULTING PROPRIETARY 2,498,750 24 months from quotation date
APEX
FUND
SERVICES
PTY
LTD
EMERGING\
COMPANIES>
9,995,000 24 months from quotation date
CAPITAL CORPORATION (HOLDINGS) PTY LTD 500,000 24 months from quotation date
KIMBERLEY DAWN HANLY + THOMAS SYLVANUS HANLY HANLY INVESTMENT TRUST> 150,000 24 months from quotation date
KIMBERLEY DAWN HANLY + THOMAS SYLVANUS HANLY HANLY INVESTMENT TRUST> 5,097,450 24 months from quotation date
MARK MUZZIN + CHRISTINA ANNE MUZZIN + TOMAS MUZZIN
17,991,000 24 months from quotation date
MARK MUZZIN + CHRISTINA ANNE MUZZIN + TOMAS MUZZIN
17,991,000 24 months from quotation date
MARK ANTHONY MUZZIN 2 24 months from quotation date
MARK ANTHONY MUZZIN 1,000,000 24 months from quotation date
MAVIX PTY LTD 999,500 24 months from quotation date
MISHTALEM PTY LTD 99,950 24 months from quotation date
EVELYNE JEAN TYMMS 99,950 24 months from quotation date
MM&R SERVICES PTY LTD 99,950 24 months from quotation date
MOSHE TUVYA AMZALAK 199,900 24 months from quotation date
KRISTIE LAUREN HANNAH 99,950 24 months from quotation date
NON CORRELATED CAPITAL PTY LTD 1,999,000 24 months from quotation date
NON CORRELATED CAPITAL PTY LTD 1,332,667 24 months from quotation date
PRIYANKA BHUSHAN GUPTA 1,250,000 24 months from quotation date
PROVISION ADVISORY PROPRIETARY 2,498,750 24 months from quotation date
RACHEL AMZALAK 24,988 24 months from quotation date
RAJESH RAMANATHAN 999,500 24 months from quotation date
RUTHIE PTY LTD 774,613 24 months from quotation date
SCRATCHING AROUND 4 RETURNS PTY LTD A/C> 999,500 24 months from quotation date
SEISMIC ENTERPRISES PTY LTD 1,999,000 24 months from quotation date
SPARK PLUS PTE LTD 499,750 24 months from quotation date
THOMAS WILLIAM WALKER 99,950 24 months from quotation date
TOVA MIRIAM LEUCHTER 199,900 24 months from quotation date
VIDOG CAPITAL PTY LTD 2,598,700 24 months from quotation date
VIRUL CAPITAL PTY LTD 666,334 24 months from quotation date
VORIAN
INVESTMENT
(HOLDINGS)
PTY
LTD
INVESTMENT A/C>
9,950,000 24 months from quotation date
ARACHCHIGE WEERANTHUNGE 999,500 24 months from quotation date
WENDY PATRICIA FIGUEROA 99,950 24 months from quotation date
WINSOME MARY SANTA MARIA 9,995,000 24 months from quotation date
WINSOME MARY SANTA MARIA 125,000 24 months from quotation date
OSCHIE CAPITAL PTY LIMITED 4,997,500 24 months from quotation date